OPKO Health's (OPK) "Buy" Rating Reiterated at HC Wainwright

OPKO Health (NASDAQ:OPK - Get Free Report)'s stock had its "buy" rating reissued by equities researchers at HC Wainwright in a research report issued to clients and investors on Wednesday,Benzinga reports. They presently have a $3.00 price objective on the biotechnology company's stock. HC Wainwright's target price points to a potential upside of 102.70% from the stock's current price.

A number of other research firms have also recently issued reports on OPK. Barrington Research reiterated an "outperform" rating and issued a $2.25 price objective on shares of OPKO Health in a report on Friday, November 8th. StockNews.com upgraded OPKO Health from a "sell" rating to a "hold" rating in a research report on Tuesday. Finally, Piper Sandler reiterated an "overweight" rating and set a $3.00 price target on shares of OPKO Health in a research report on Tuesday, September 17th.

OPKO Health Price Performance

Shares of NASDAQ:OPK traded down $0.03 on Wednesday, hitting $1.48. The company's stock had a trading volume of 1,897,034 shares, compared to its average volume of 2,813,289. The company has a market capitalization of $1.01 billion, a PE ratio of -7.79 and a beta of 1.63. The company has a debt-to-equity ratio of 0.30, a current ratio of 2.97 and a quick ratio of 2.69. The company has a 50-day simple moving average of $1.54 and a 200 day simple moving average of $1.50. OPKO Health has a 1 year low of $0.86 and a 1 year high of $1.76.

Insider Activity

In other news, CEO Phillip Md Et Al Frost purchased 100,000 shares of the stock in a transaction that occurred on Thursday, November 14th. The stock was bought at an average cost of $1.62 per share, for a total transaction of $162,000.00. Following the acquisition, the chief executive officer now directly owns 211,612,405 shares of the company's stock, valued at $342,812,096.10. This represents a 0.05 % increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Over the last three months, insiders have purchased 1,304,255 shares of company stock valued at $2,024,605. 47.26% of the stock is currently owned by insiders.

Institutional Investors Weigh In On OPKO Health

A number of large investors have recently added to or reduced their stakes in OPK. CIBC Asset Management Inc increased its stake in shares of OPKO Health by 79.1% during the second quarter. CIBC Asset Management Inc now owns 20,322 shares of the biotechnology company's stock valued at $25,000 after buying an additional 8,978 shares during the period. American Century Companies Inc. bought a new stake in OPKO Health in the second quarter valued at $112,000. Y.D. More Investments Ltd purchased a new position in OPKO Health during the 2nd quarter valued at $1,840,000. Hollencrest Capital Management raised its holdings in OPKO Health by 14.0% in the 2nd quarter. Hollencrest Capital Management now owns 90,000 shares of the biotechnology company's stock worth $112,000 after purchasing an additional 11,020 shares in the last quarter. Finally, Rubric Capital Management LP lifted its position in shares of OPKO Health by 800.0% in the 2nd quarter. Rubric Capital Management LP now owns 44,422,304 shares of the biotechnology company's stock worth $55,528,000 after purchasing an additional 39,486,490 shares during the period. Institutional investors own 64.63% of the company's stock.

OPKO Health Company Profile

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.